5-fluoro-1-nitro-2-(propan-2-yloxy)benzene | 1092496-27-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-fluoro-1-nitro-2-(propan-2-yloxy)benzene
• 英文别名: 4-Fluoro-1-isopropoxy-2-nitrobenzene；4-fluoro-2-nitro-1-propan-2-yloxybenzene
• CAS: 1092496-27-9
• 化学式: C₉H₁₀FNO₃
• 分子量: 199.182
• InChiKey: GSHDLWCUKNQEKB-UHFFFAOYSA-N

物化性质

• 沸点：
  291.8±20.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-fluoro-1-nitro-2-(propan-2-yloxy)benzene 在 sodium tetrahydroborate 、 10% Pd/C 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents

  摘要：

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.093
• 作为产物：
  描述：

  2,5-二氟硝基苯 、 异丙醇 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-fluoro-1-nitro-2-(propan-2-yloxy)benzene
  参考文献：
  名称：

  Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents

  摘要：

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.093

文献信息

• [EN] NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013150036A1

  公开（公告）日：2013-10-10

  The present invention relates to compounds of formula (I): wherein R6 is -CONH2 or a -C(Rα)(Rβ)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.

  本发明涉及式(I)化合物的制备过程及其治疗用途：其中R6是-CONH2或一个-C(Rα)(Rβ)(OH)基团；R是一个取代的苯基或杂芳基团；R7是一个可选地取代的芳基或杂芳基团。
• NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF
  申请人：CARRY Jean-Christophe

  公开号：US20130261106A1

  公开（公告）日：2013-10-03

  The present invention relates to compounds of formula (I): wherein R6 is —CONH 2 or a —C(R α )(R β )(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.

  本发明涉及具有公式(I)的化合物： 其中R6是—CONH2或—C(Rα)(Rβ)(OH)基团；R是取代的苯基或杂芳基团；R7是可选地取代的芳基或杂芳基团。 其制备过程及其治疗用途。
• QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
  申请人：Otsubo Kenji

  公开号：US20100130546A1

  公开（公告）日：2010-05-27

  The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R 1 represents a hydrogen atom, etc.; R 2 represents a hydrogen atom, etc.; R 3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R 4 represents a halogen atom; R 5 represents a hydrogen atom or halogen atom; R 6 represents a hydrogen atom; and R 7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.

  本发明提供了一种喹诺酮化合物，其由通式（1）或其盐所表示，其中R1表示氢原子等；R2表示氢原子等；R3表示苯基，该苯基可以选择性地被一个或多个取代基取代等；R4表示卤素原子；R5表示氢原子或卤素原子；R6表示氢原子；R7表示羟基等。该喹诺酮化合物具有功能改善效果，通过抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而延长首次给药前的期间，抑制神经功能障碍的进展。
• Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
  申请人：SANOFI

  公开号：US09115140B2

  公开（公告）日：2015-08-25

  The present invention relates to compounds of formula (I): wherein R6 is —CONH2 or a —C(Rα)(Rβ)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.

  本发明涉及式(I)的化合物：其中R6是—CONH2或—C(Rα)(Rβ)(OH)基团；R是取代苯基或杂环基团；R7是可选取代的芳基或杂环基团。本发明还涉及制备这些化合物的方法和治疗应用。
• US8269011B2
  申请人：——

  公开号：US8269011B2

  公开（公告）日：2012-09-18